about
Reduction of vinblastine neurotoxicity in mice utilizing a collagen matrix carrierIntra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma originA multi-modality approach for the treatment of AIDS.Forbeck forum on improved drug delivery to brain tumors.A pharmacologic approach to dosage intensification.Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain.Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil.Utility of topical formulations of morphine hydrochloride containing azone and N-methyl-2-pyrrolidone.Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule.A pilot clinical and pharmacokinetic study of intracarotid cisplatin and bleomycin.A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects.The uptake and efflux of doxorubicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline.HPLC and flow cytometric analyses of uptake of adriamycin and menogaril by monolayers and multicell spheroids.Anti-tumor effect of cisplatin, carboplatin, mitoxantrone, and doxorubicin on peritoneal tumor growth after intraperitoneal and intravenous chemotherapy: a comparative study.Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin.Preclinical toxicity study of mitomycin C infused into the internal carotid artery of beagle dogs.Single and combination treatment with vitamin K3 and adriamycin: in vitro effects on cell survival and DNA damage in human chronic myeloid leukemia cells.Steady-state arterial and hepatic venous plasma concentrations of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine in animals--drugs which are subject to both splanchnic and extra-splanchnic elimination.Dissolution and stability of carmustine in the absence of ethanol.Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.Low-dose systemic doxorubicin in combination with regional hepatic hyperthermia.Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumor.Expression of the multidrug transporter P-glycoprotein and in vitro chemosensitivity: correlation with in vivo response to chemotherapy in acute myeloid leukemia.Cellular viability in human tumor micro-organ cultures: in situ quantitation by image processing.Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery.Detection of P-glycoprotein with JSB-1 monoclonal antibody in B-5 fixed and paraffin-embedded cell lines and tissues.Evaluation of quinidine effect on the antitumor activity of adriamycin and mitoxantrone in adriamycin-sensitive and -resistant P388 leukemia cells.Reversal of doxorubicin and cisplatin resistance in vivo in murine leukemias by the calcium antagonist RO 11-2933.Effect of verapamil on the uptake and efflux of etoposide (VP16) in both sensitive and resistant cancer cellsOvercoming murine tumor cell resistance to vinblastine by presentation of the drug in multilamellar liposomes consisting of phosphatidylcholine and phosphatidylserineAmelioration of doxorubicin resistance by pentoxifylline in human chronic myeloid leukemia cells in vitroReduction by norepinephrine of the side effects induced by combined hepatic arterial administration of degradable strach microspheres and adriamycin in rats with a liver adenocarcinomaToxicity and antitumor activity of liposome-entrapped retinoid Ro13-7410A model for mimicking the pharmacokinetics of chemotherapy drugs for evaluation of drug effects in a soft agar colony formation assay systemEffect of induced acidosis on cytotoxicity of anticancer drugsExtravasation of doxorubicin from vascular access devicesSuppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatmentsLiposome-incorporated 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine as a slow-release anti-tumor drug depot in rat liver macrophagesTargeting behavior of hepatic artery injected temperature sensitive liposomal adriamycin on tumor-bearing rats
P1433
Q28330977-4987BD07-8E07-4F9A-8064-798D05271C57Q28341982-C2854A33-EEC2-4528-ABEE-63C73A1C0ED4Q37404045-E9889C78-4036-4904-AC66-CB4D7689C2EEQ37609335-5F946542-7E9A-4B30-B6AD-AB31CFCBC4CFQ38027548-43B7A18E-1527-418F-8183-E9A639BBB9C6Q39305161-49AA92AF-31AC-4797-B7E0-2D4C6A885D66Q39512800-839E5CAE-125B-4C35-AB2A-5D41557D3B8CQ39527874-C684A4A1-BDCF-4EE6-86CD-AEDD62CEAF9FQ41171982-EB2064AC-1B8B-4A94-819E-3F260B91B8CDQ41172396-AB13D7D2-2A77-4B9B-AEF8-DD2CD01B05C5Q41251776-321FF97F-824B-4410-9208-8944791B2890Q41705094-D2A66D6E-54EA-401D-BD8C-130371B9F329Q41753696-AE6128C2-398A-4B6B-9478-D8BB92B2E88AQ41874542-1B012256-8960-492A-AE14-11EEA4612FCAQ42635459-16B2B161-B263-4241-B8A0-2676D464D71EQ44559447-94E12F36-EC2E-45F7-AE3E-22EAD5AF222FQ45036713-3B723054-6316-4FCB-88F7-FE41729A10CCQ45271237-50AB4D15-5A68-4B6B-B36F-8AD905B60030Q45932878-D97CF1CA-BC0C-44F8-BE9F-7E2CBD79A594Q46464045-71969686-B762-413A-B7FC-E0CEB2F0BC50Q46614803-FEBB53E2-7BD3-4459-BCD3-71336FD12466Q50590598-43D56E55-7C8F-4492-B668-F22018C42770Q50876004-7E54CDCE-5DD0-4FAE-B564-BE649194F0D8Q50876287-14928FB3-8B6C-40B3-B154-F8FB661E02DEQ52545239-8AE0CAB2-500C-4881-AD0D-5A1DE57093D4Q54308487-CCF656E3-DA20-4E77-8199-A32BA4EDD93FQ54308792-4D7F2784-59A6-4C84-8BFB-D58A968AE2FFQ54333044-D4440CC3-7C45-4F2E-9BA6-44F0462B8140Q54337383-71E74E3F-6E2C-4C39-AF62-C60BACECE70BQ67785577-F6C7414B-E91A-4961-8125-36964ADD697AQ67823912-B6886255-2DA0-4F09-B008-4939004393FAQ67823917-451CDF94-6626-44E3-8E09-BC6EE9246737Q67823920-4086385D-10DD-4681-8838-FB5DC5ADB672Q67895199-1FB67091-61DF-402E-8DCF-7AD35682ED6AQ67895200-7881A61C-05D4-46ED-B886-42253685C9DCQ68020877-C73EC0EB-B39E-49FF-9B3E-E45BB62702D8Q68020879-F2D629F3-51B0-4D48-BB4A-890C237BCA03Q68020882-11F74F95-84A8-4636-8C5A-91D592056217Q68418152-5BDFA0DC-7A03-49C1-B882-09973F7643FAQ68666563-1D92C602-8E7E-4E2B-A839-FCC24138A17C
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Mary Ann Liebert, Inc.
@nl
wissenschaftliche Fachzeitschrift
@de
name
Selective cancer therapeutics
@ast
Selective cancer therapeutics
@en
Selective cancer therapeutics
@es
Selective cancer therapeutics
@it
Selective cancer therapeutics
@nl
type
label
Selective cancer therapeutics
@ast
Selective cancer therapeutics
@en
Selective cancer therapeutics
@es
Selective cancer therapeutics
@it
Selective cancer therapeutics
@nl
altLabel
Sel Cancer Ther
@en
prefLabel
Selective cancer therapeutics
@ast
Selective cancer therapeutics
@en
Selective cancer therapeutics
@es
Selective cancer therapeutics
@it
Selective cancer therapeutics
@nl
P1055
P1156
P1476
Selective cancer therapeutics
@en